Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide - approved to treat Type 2 Diabetes ("T2D") under the brand name ...

GLP-1 receptor agonists are synthetic drugs that mimic ... It’ll also be available as an ingredient for manufacturers, allowing brands to incorporate it into everyday foods like snacks, shakes ...

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor, distinct from any previously ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing ...